TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)

Ilaria Colombo, Kira‐Lee Koster, Lisa Holer, Simon Haefliger, Manuela Rabaglio, Sara Bastian, Michael Schwitter, Katrin Eckhardt, Stefanie Hayoz, Anna M. Mc Laughlin, Charlotte Kloft, Marian Klose, Stéfan Halbherr, Christian Baumgärtner, Cristiana Sessa, Anastasios Stathis, Dagmar Hess, Markus Joerger